NASDAQ:SLDB Solid Biosciences Q3 2026 Earnings Results & Report $6.84 0.00 (0.00%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$6.84 +0.00 (+0.07%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Solid Biosciences beat analyst earnings expectations in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$0.36 versus the -$0.4093 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 4, 2026TimeAfter Market ClosesConference Call7:00 AM ET Solid Biosciences EPS ResultsActual EPS-$0.36Consensus EPS -$0.4093Beat/MissBeat by +$0.0493One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersSolid Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Solid Biosciences Q3 2026 Earnings FAQ Did Solid Biosciences beat earnings estimates for Q3 2026? Solid Biosciences (NASDAQ:SLDB) reported earnings of -$0.36 per share for Q3 2026, beating the consensus estimate of -$0.4093. The report was announced on Wednesday, November 4, 2026. Solid Biosciences Earnings HeadlinesWilliam Blair Begins Coverage on Solid Biosciences (NASDAQ:SLDB)November 11, 2026 | americanbankingnews.comH.C. Wainwright Sticks to Their Buy Rating for Solid Biosciences (SLDB)November 10, 2026 | theglobeandmail.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today. | Profits Run (Ad)Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare ConferenceNovember 10, 2026 | globenewswire.comSolid Biosciences (SLDB) Gets a Buy from RBC CapitalNovember 9, 2026 | theglobeandmail.comSolid Biosciences a new Outperform at William Blair on Duchenne assetNovember 9, 2026 | msn.comSee More Solid Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Solid Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Solid Biosciences and other key companies, straight to your email. Email Address About Solid BiosciencesSolid Biosciences (NASDAQ:SLDB) is a biotechnology company developing genetic medicines for Duchenne muscular dystrophy and other serious neuromuscular and cardiac diseases. The company’s research focuses on gene-transfer approaches intended to address underlying causes of these conditions. Its lead program, SGT-003, is an investigational gene therapy being developed for Duchenne muscular dystrophy. Solid Biosciences also has research programs targeting other rare diseases. These programs are in development, and its therapies have not been established as approved treatments. Founded in 2013 and based in the United States, Solid Biosciences conducts research and clinical development in the rare-disease field. Its work includes evaluating investigational treatments through clinical studies.View Solid Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.